Welcome to our dedicated page for Iterum Therapeutics news (Ticker: ITRM), a resource for investors and traders seeking the latest updates and insights on Iterum Therapeutics stock.
Iterum Therapeutics plc reports developments tied to its anti-infective business, its ORLYNVAH™ commercial activity, and its corporate status as a company in provisional liquidation. The company has focused on oral and IV antibiotics for infections caused by multi-drug resistant pathogens, including sulopenem and ORLYNVAH™ for uncomplicated urinary tract infections in adult women with limited or no alternative oral antibacterial treatment options.
Recurring updates include ORLYNVAH™ market access, pharmacy benefit manager and specialty-distributor contracting, patent protection for sulopenem etzadroxil and probenecid tablet technology, FDA correspondence on product claims, financial results, Nasdaq listing matters, and the Irish winding-up petition and provisional liquidator appointments.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Dublin, Ireland and Chicago, April 20, 2023 – Iterum Therapeutics (Nasdaq: ITRM) announced the presentation of two posters at the 33rd Annual European Congress of Clinical Microbiology and Infectious Disease (ECCMID) in Copenhagen on April 17, 2023. The presentations focused on a novel analysis method called Desirability of Outcome Ranking (DOOR) applied to Phase 3 trials of their antibiotic sulopenem for uncomplicated (uUTI) and complicated urinary tract infections (cUTI). Key findings demonstrated that oral sulopenem was more effective than ciprofloxacin for uUTI and comparable to ertapenem for cUTI. This approach, though not yet a primary endpoint for regulatory approval, reflects a commitment to evaluating patient outcomes comprehensively. Iterum is advancing sulopenem, an innovative treatment for multi-drug resistant infections, with QIDP and Fast Track designations for multiple indications.